Skip to main content
Erschienen in: Cancer Causes & Control 5/2013

01.05.2013 | Original paper

Clinical trial discussion, referral, and recruitment: physician, patient, and system factors

verfasst von: Celia P. Kaplan, Anna Maria Nápoles, Daniel Dohan, E. Shelley Hwang, Michelle Melisko, Dana Nickleach, Jessica Ann Quinn, Jennifer Haas

Erschienen in: Cancer Causes & Control | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patient participation in cancer clinical trials is imperative to the advancement of medical science. Physicians play an important role in recruitment by discussing clinical trials with their cancer patients. Patient–physician discussion is influenced by many factors relating to the physician, the patient, and the healthcare system.

Methods

Physicians selected from the 2008–2009 American Medical Association Physician Masterfile who practiced in California, Florida, Illinois, or New York and specialized in medical oncology, surgery, or radiation oncology were surveyed about their attitudes and practices with respect to breast cancer clinical trials. Practice types were categorized according to the classifications provided by the American College of Surgeons, and clinical trial and practice addresses were geocoded.

Results

Surveys were completed by 706 of 1,534 eligible physicians (46 %). Medical oncologists were more likely than surgical or radiation oncologists to discuss the possibility, benefits, and risks of clinical trial enrollment with their breast cancer patients. Physicians who spent the most time in patient care were least likely to discuss clinical trials with their patients. Distance from a physician’s practice to the nearest clinical trial site was inversely associated with referral and recruitment. Perceived barriers to clinical trial participation were associated with greater referral activity suggesting that physicians who were more involved in trials were also more likely to understand barriers to participation.

Conclusions

Multilevel interventions may be successful at increasing participation of women in clinical trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Foley JF, Moertel CG (1991) Improving accrual into cancer clinical trials. J Cancer Educ 6:165–173CrossRefPubMed Foley JF, Moertel CG (1991) Improving accrual into cancer clinical trials. J Cancer Educ 6:165–173CrossRefPubMed
2.
Zurück zum Zitat Siminoff LA, Zhang A, Colabianchi N, Sturm CM, Shen Q (2000) Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 18:1203–1211PubMed Siminoff LA, Zhang A, Colabianchi N, Sturm CM, Shen Q (2000) Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 18:1203–1211PubMed
3.
Zurück zum Zitat Nguyen TT, Somkin CP, Ma Y (2005) Participation of Asian-American women in cancer chemoprevention research: physician perspectives. Cancer 104:3006–3014CrossRefPubMed Nguyen TT, Somkin CP, Ma Y (2005) Participation of Asian-American women in cancer chemoprevention research: physician perspectives. Cancer 104:3006–3014CrossRefPubMed
4.
Zurück zum Zitat Howerton MW, Gibbons MC, Baffi CR, Gary TL, Lai GY, Bolen S, Tilburt J, Tanpitukpongse TP, Wilson RF, Powe NR, Bass EB, Ford JG (2007) Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer 109:465–476CrossRefPubMed Howerton MW, Gibbons MC, Baffi CR, Gary TL, Lai GY, Bolen S, Tilburt J, Tanpitukpongse TP, Wilson RF, Powe NR, Bass EB, Ford JG (2007) Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer 109:465–476CrossRefPubMed
5.
Zurück zum Zitat Sherwood PR, Given BA, Scholnik A, Given CW (2004) To refer or not to refer: factors that affect primary care provider referral of patients with cancer to clinical treatment trials. J Cancer Educ 19:58–65CrossRefPubMed Sherwood PR, Given BA, Scholnik A, Given CW (2004) To refer or not to refer: factors that affect primary care provider referral of patients with cancer to clinical treatment trials. J Cancer Educ 19:58–65CrossRefPubMed
6.
Zurück zum Zitat Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, Smith D, Brown DR (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052CrossRefPubMed Simon MS, Du W, Flaherty L, Philip PA, Lorusso P, Miree C, Smith D, Brown DR (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052CrossRefPubMed
7.
Zurück zum Zitat Lara P, Higdon R, Lim N, Kwan K, Tanaka M, Lau D, Wun T, Welborn J, Meyers FJ, Christensen S (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19:1728–1733PubMed Lara P, Higdon R, Lim N, Kwan K, Tanaka M, Lau D, Wun T, Welborn J, Meyers FJ, Christensen S (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19:1728–1733PubMed
8.
Zurück zum Zitat Mannel RS, Walker J, Gould N, Scribner DR, Kamelle S, Tillmanns T, McMeeking S, Gold M (2003) Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol 26:171–173CrossRefPubMed Mannel RS, Walker J, Gould N, Scribner DR, Kamelle S, Tillmanns T, McMeeking S, Gold M (2003) Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol 26:171–173CrossRefPubMed
9.
Zurück zum Zitat Martin RC, Polk HC, Jaques DP (2003) Does additional surgical training increases participation in randomized controlled trials? Am J Surg 185:239–243CrossRefPubMed Martin RC, Polk HC, Jaques DP (2003) Does additional surgical training increases participation in randomized controlled trials? Am J Surg 185:239–243CrossRefPubMed
10.
Zurück zum Zitat Ramirez AG, Wildes K, Talavera G, Napoles-Springer A, Gallion K, Perez-Stable EJ (2008) Clinical trials attitudes and practices of Latino physicians. Contemp Clin Trials 29:482–492CrossRefPubMed Ramirez AG, Wildes K, Talavera G, Napoles-Springer A, Gallion K, Perez-Stable EJ (2008) Clinical trials attitudes and practices of Latino physicians. Contemp Clin Trials 29:482–492CrossRefPubMed
11.
Zurück zum Zitat Klabunde CN, Keating NL, Potosky AL, Ambs A, He Y, Hornbrook MC, Ganz PA (2011) A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst 103:384–397CrossRefPubMed Klabunde CN, Keating NL, Potosky AL, Ambs A, He Y, Hornbrook MC, Ganz PA (2011) A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst 103:384–397CrossRefPubMed
12.
Zurück zum Zitat Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, Hunt KK, Giuliano AE (2005) Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg 190:539–542CrossRefPubMed Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, Hunt KK, Giuliano AE (2005) Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg 190:539–542CrossRefPubMed
13.
Zurück zum Zitat Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D (2005) Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer 6:45–54CrossRefPubMed Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D (2005) Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer 6:45–54CrossRefPubMed
14.
Zurück zum Zitat Pinto HA, McCaskill-Stevens W, Wolfe P, Marcus AC (2000) Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative. Ann Epidemiol 10:S78–S84CrossRefPubMed Pinto HA, McCaskill-Stevens W, Wolfe P, Marcus AC (2000) Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative. Ann Epidemiol 10:S78–S84CrossRefPubMed
15.
Zurück zum Zitat Malat J, van Ryn M (2005) African-American preference for same-race healthcare providers: the role of healthcare discrimination. Ethn Dis 15:740–747PubMed Malat J, van Ryn M (2005) African-American preference for same-race healthcare providers: the role of healthcare discrimination. Ethn Dis 15:740–747PubMed
16.
Zurück zum Zitat American Cancer Society (2012) Clinical trials: state laws about insurance coverage. American Cancer Society, Atlanta American Cancer Society (2012) Clinical trials: state laws about insurance coverage. American Cancer Society, Atlanta
17.
Zurück zum Zitat Monheit AC, Vistnes JP (2000) Race/ethnicity and health insurance status: 1987 and 1996. Med Care Res Rev 57(Suppl 1):11–35PubMed Monheit AC, Vistnes JP (2000) Race/ethnicity and health insurance status: 1987 and 1996. Med Care Res Rev 57(Suppl 1):11–35PubMed
18.
Zurück zum Zitat Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ (2002) Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95:989–996CrossRefPubMed Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ (2002) Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95:989–996CrossRefPubMed
Metadaten
Titel
Clinical trial discussion, referral, and recruitment: physician, patient, and system factors
verfasst von
Celia P. Kaplan
Anna Maria Nápoles
Daniel Dohan
E. Shelley Hwang
Michelle Melisko
Dana Nickleach
Jessica Ann Quinn
Jennifer Haas
Publikationsdatum
01.05.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0173-5

Weitere Artikel der Ausgabe 5/2013

Cancer Causes & Control 5/2013 Zur Ausgabe

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.